TROV vs. OMGA, HLVX, DBVT, ELUT, ALVR, LENZ, CGTX, PLX, IKNA, and TIL
Should you be buying Cardiff Oncology stock or one of its competitors? The main competitors of Cardiff Oncology include Omega Therapeutics (OMGA), HilleVax (HLVX), DBV Technologies (DBVT), Elutia (ELUT), AlloVir (ALVR), LENZ Therapeutics (LENZ), Cognition Therapeutics (CGTX), Protalix BioTherapeutics (PLX), Ikena Oncology (IKNA), and Instil Bio (TIL). These companies are all part of the "medical" sector.
Cardiff Oncology (NASDAQ:TROV) and Omega Therapeutics (NASDAQ:OMGA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, earnings, dividends, profitability, risk, valuation, analyst recommendations and community ranking.
In the previous week, Omega Therapeutics had 2 more articles in the media than Cardiff Oncology. MarketBeat recorded 2 mentions for Omega Therapeutics and 0 mentions for Cardiff Oncology. Omega Therapeutics' average media sentiment score of 1.24 beat Cardiff Oncology's score of 0.00 indicating that Omega Therapeutics is being referred to more favorably in the news media.
Omega Therapeutics has a net margin of -1,868.35% compared to Cardiff Oncology's net margin of -3,688.31%. Omega Therapeutics' return on equity of -136.04% beat Cardiff Oncology's return on equity.
Omega Therapeutics has a consensus price target of $10.40, suggesting a potential upside of 441.67%. Given Omega Therapeutics' higher possible upside, analysts clearly believe Omega Therapeutics is more favorable than Cardiff Oncology.
10.0% of Cardiff Oncology shares are held by institutional investors. Comparatively, 97.5% of Omega Therapeutics shares are held by institutional investors. 0.6% of Cardiff Oncology shares are held by insiders. Comparatively, 57.0% of Omega Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Cardiff Oncology has higher earnings, but lower revenue than Omega Therapeutics. Omega Therapeutics is trading at a lower price-to-earnings ratio than Cardiff Oncology, indicating that it is currently the more affordable of the two stocks.
Cardiff Oncology has a beta of 1.04, indicating that its stock price is 4% more volatile than the S&P 500. Comparatively, Omega Therapeutics has a beta of 1.9, indicating that its stock price is 90% more volatile than the S&P 500.
Cardiff Oncology received 378 more outperform votes than Omega Therapeutics when rated by MarketBeat users. Likewise, 73.09% of users gave Cardiff Oncology an outperform vote while only 72.73% of users gave Omega Therapeutics an outperform vote.
Summary
Omega Therapeutics beats Cardiff Oncology on 12 of the 17 factors compared between the two stocks.
Get Cardiff Oncology News Delivered to You Automatically
Sign up to receive the latest news and ratings for TROV and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TROV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cardiff Oncology Competitors List
Related Companies and Tools
